MRNA241206P46000
- 1.33
- 0.000.00%
Moderna Newsroom
Palantir, MicroStrategy, and Axon Added to the Nasdaq 100 Index
MicroStrategy, Palantir, Axon Added To Nasdaq 100: Super Micro Computer, Moderna, Illumina Exit The Index
Bitcoin drives stock prices soaring! MicroStrategy (MSTR.US) successfully enters the NASDAQ 100 Index.
MicroStrategy will be included in the Technology-focused NASDAQ 100 Index, with this change taking effect before the market opens on December 23.
The adjustment of the Nasdaq 100 constituent stocks has been announced! Popular stocks Palantir and MSTR have been added, while Super Micro Computer and others have been removed.
The three companies that are being added are Palantir, MicroStrategy, and Axon; Illumina, Super Micro Computer, and Moderna will be removed.
Express News | The components of the NASDAQ 100 Index will include Palantir, MicroStrategy, and Axon.
Express News | Nasdaq Inc: As a Result of Reconstitution, Following Three Companies Will Be Removed From Index: Illumina, Inc., Super Micro Computer, Inc., and Moderna, Inc
Annual Changes to the Nasdaq-100 Index
Moderna Options Spot-On: On December 12th, 121.57K Contracts Were Traded, With 723.43K Open Interest
On December 12th ET, $Moderna(MRNA.US)$ had active options trading, with a total trading volume of 121.57K options for the day, of which put options accounted for 87.04% of the total transactions,
Carisma Downgraded by Baird Over Lack of Near-term Catalysts
MicroStrategy Shares Could Surge Even Higher If Added to Nasdaq 100 on Friday, Crypto Analyst Says
Super Micro Computer Teeters On Edge Of Nasdaq 100: Can XAI, Nvidia Help Stabilize Trajectory?
MicroStrategy Stock Could Get Added to the Nasdaq 100 Because of a Quirk
Unusual Options Activity: ACI, FTI and Others Attract Market Bets, ACI V/OI Ratio Reaches 75.0
EST Dec 11th Morning Delivery - In the last two hours of trading, 9 options with a high V/OI ratio were detected. With the market volatile, it's crucial to stay informed on the latest options trends.
Moderna Reinstated With an Underperform at BofA
BofA Securities Initiates Moderna(MRNA.US) With Sell Rating, Announces Target Price $41
BofA Downgrades Moderna, Says It's 'Tough Time' to Be Vaccine Maker
BofA Restarts Coverage of 11 Large-cap Biopharmas
FDA Highlights Safety Challenges And Development Needs For Pediatric RSV Vaccines Amid Historical Concerns And Recent MRNA Trial Pauses; Focus On Addressing Unmet Needs For Infants And Toddlers.
Unpacking the Latest Options Trading Trends in Moderna
Expert Outlook: Moderna Through The Eyes Of 19 Analysts